CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome

5Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Defects in the DOCK8 gene causes combined immunodeficiency termed DOCK8 immunodeficiency syndrome (DIDS). DIDS previously belonged to the disease category of autosomal recessive hyper IgE syndrome (AR-HIES) but is now classified as a combined immunodeficiency (CID). This genetic disorder induces early onset of susceptibility to severe recurrent viral and bacterial infections, atopic diseases and malignancy resulting in high morbidity and mortality. This pathological state arises from impairment of actin polymerization and cytoskeletal rearrangement, which induces improper immune cell migration-, survival-, and effector functions. Owing to the severity of the disease, early allogenic hematopoietic stem cell transplantation is recommended even though it is associated with risk of unintended adverse effects, the need for compatible donors, and high expenses. So far, no alternative therapies have been developed, but the monogenic recessive nature of the disease suggests that gene therapy may be applied. The advent of the CRISPR/Cas gene editing system heralds a new era of possibilities in precision gene therapy, and positive results from clinical trials have already suggested that the tool may provide definitive cures for several genetic disorders. Here, we discuss the potential application of different CRISPR/Cas-mediated genetic therapies to correct the DOCK8 gene. Our findings encourage the pursuit of CRISPR/Cas-based gene editing approaches, which may constitute more precise, affordable, and low-risk definitive treatment options for DOCK8 deficiency.

References Powered by Scopus

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

12502Citations
N/AReaders
Get full text

Multiplex genome engineering using CRISPR/Cas systems

12182Citations
N/AReaders
Get full text

Search-and-replace genome editing without double-strand breaks or donor DNA

2891Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Deciphering the role of DOCK8 in tumorigenesis by regulating immunity and the application of nanotechnology in DOCK8 deficiency therapy

3Citations
N/AReaders
Get full text

STAT3 Hyper-IgE Syndrome and DOCK8 Immunodeficiency Syndrome: A Review

0Citations
N/AReaders
Get full text

Clinical, immunological, and genetic description of a Mexican cohort of patients with DOCK8 deficiency

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022). CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome. Frontiers in Genome Editing, 4. https://doi.org/10.3389/fgeed.2022.793010

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

71%

Professor / Associate Prof. 1

14%

Lecturer / Post doc 1

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

38%

Biochemistry, Genetics and Molecular Bi... 3

38%

Immunology and Microbiology 1

13%

Environmental Science 1

13%

Save time finding and organizing research with Mendeley

Sign up for free